#Terns Pharmaceuticals

Merck's $6.7 Billion Acquisition of Terns Pharmaceuticals: Implications for Oncology Infrastructure

Merck's acquisition of Terns Pharmaceuticals for $6.7 billion is a strategic move to bolster its oncology portfolio, particularly in leukemia treatment.